Nitinotes completes first commercial EndoZip cases in Germany

Nitinotes said it has completed the first commercial German cases for EndoZip, its automated suturing system for Endoscopic Sleeve Gastroplasty, at University Medical Centre Mannheim. The launch makes Germany the fourth European market for EndoZip and expands the device’s commercial footprint in a major obesity treatment market.

Why it matters: - Germany is one of Europe’s largest obesity treatment markets, so the commercial launch could expand access to Endoscopic Sleeve Gastroplasty. - EndoZip is designed to automate key suturing steps while keeping physician control, which may make ESG easier to deliver in more clinical settings. - Nitinotes says broader adoption could help move minimally invasive obesity treatment beyond a small number of specialized centers.

What happened: - Nitinotes announced the successful completion of the first commercial EndoZip cases in Germany on July 9, 2026. - The procedures took place at University Medical Centre Mannheim. - Prof. Dr. Sebastian Belle and Dr. Christine Stier performed the cases. - Germany is the fourth European market to introduce EndoZip commercially, after Italy, Spain and France. - Nitinotes is a privately held medical device company based in Caesarea, Israel.

The details: - EndoZip is an automated endoluminal suturing system for Endoscopic Sleeve Gastroplasty. - ESG is a minimally invasive, incision-free procedure that reduces stomach volume with an endoscopic suturing approach while preserving normal anatomy. - EndoZip was developed to automate key suturing steps while maintaining physician control of the procedure. - The system supports a single-operator workflow that may improve procedural efficiency and consistency. - EndoZip is CE marked for use in Europe. - In the U.S., EndoZip remains investigational and is being evaluated in the EASE pivotal clinical trial under an FDA-approved Investigational Device Exemption. - A more detailed company overview is available in the company's announcement.

Between the lines: - The German launch signals continued European commercial momentum for Nitinotes after earlier rollouts in three other markets. - The company is positioning EndoZip around two buyer priorities: procedural consistency and broader physician adoption. - The physician quotes suggest the technology’s pitch is not just automation, but wider reproducibility across different care settings.

What's next: - Nitinotes said it plans to expand EndoZip adoption across additional centers in Europe. - The company also faces continued U.S. clinical evaluation before any broader American commercialization. - Physicians at Mannheim said they will further evaluate EndoZip’s role in expanding minimally invasive obesity treatment options for patients.

The bottom line: - Nitinotes has moved EndoZip into another major European market, and Germany may become a key test of whether the device can scale ESG beyond specialty centers.